Consistent with Fig. 2c, HSV-MSLN monotherapy showed significant antitumor activity and slowed tumor growth compared to the control and the MSLN-CAR T cells groups (Fig. 4b, HSV-MSLN). Here, MSLN is linked to neoplasm.